Predicting the risk of aggressive prostate cancer by analysing five protein markers, more than 100 genetic markers, and clinical data, supported by EIT Health
Stockholm3 is a blood test that increases the detection of aggressive prostate cancers by 20% and, at the same time, reduces the number of unnecessary biopsies by 50% compared to current clinical practice. Combining five protein markers, over 100 genetic markers, clinical data and a proprietary algorithm, Stockholm3 predicts the risk of aggressive prostate cancer.
The Stockholm3 test has been validated in a clinical study involving more than 58,000 participants, with results published in The Lancet Oncology, Nature Reviews Clinical Oncology and European Urology Focus, among others. The Stockholm3 test has been validated in clinical use in Sweden and Norway.
The Stockholm3 test, supported by EIT Health, won the EIT Innovators Award 2017.
Want to read more about Stockholm3?
Website: sthlm3.se/
Governments get behind EIT Award winner Stockholm3 prostate cancer test
EIT Awards winners announced: new wave of innovators changing the face of Europe
Share this page
